Alatrofloxacin
| 250px | |
| Alatrofloxacin
| |
| Systematic (IUPAC) name | |
| 7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-aminopropanoyl]amino}- 1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]- 1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine- 3-carboxylic acid | |
| Identifiers | |
| CAS number | 157605-25-9 (mesylate) |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C26H25F3N6O5 |
| Mol. mass | 558.509 g/mol |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Protein binding | 76% (trovafloxacin) |
| Metabolism | Quickly hydrolyzed to trovafloxacin |
| Half life | 9 to 12 hours (trovafloxacin) |
| Excretion | Fecal and renal (trovafloxacin) |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status |
Withdrawn |
| Routes | Intravenous |
|
WikiDoc Resources for Alatrofloxacin | |
|
Articles | |
|---|---|
|
Most recent articles on Alatrofloxacin Most cited articles on Alatrofloxacin | |
|
Media | |
|
Powerpoint slides on Alatrofloxacin | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Alatrofloxacin at Clinical Trials.gov Trial results on Alatrofloxacin Clinical Trials on Alatrofloxacin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Alatrofloxacin NICE Guidance on Alatrofloxacin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Alatrofloxacin Discussion groups on Alatrofloxacin Patient Handouts on Alatrofloxacin Directions to Hospitals Treating Alatrofloxacin Risk calculators and risk factors for Alatrofloxacin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Alatrofloxacin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.[2][3]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.
References
- ↑ PubChem CID 5489474.
- ↑ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. PMID 14568230.
- ↑ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMID 16735322.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies